You are here: Industry Insights > Keytruda

News List

NICE backing for Keytruda in classical Hodgkin lymphoma pharmatimes
July 27, 2018
The National Institute for Health and Care Excellence has recommended that MSD’s Keytruda be funded on the NHS via the Cancer Drugs Fund (CDF) for a subgroup of people with relapsed or refractory classical Hodgkin lymphoma.
Merck's Keytruda shores up head and neck case with first-line trial win biospectrumasia
July 26, 2018
Merck’s Keytruda may just be on its way to earlier use in head and neck cancer, an area where it once faced some questions.
Keytruda/chemo combo cut risk of death in NSCLC pharmatimes
July 16, 2018
MSD has unveiled further data from a trial showing that a combination of Keytruda and chemotherapy significantly improved overall survival in patients with metastatic non-squamous non-small-cell lung cancer (NSCLC).
Keytruda approved for second blood cancer pharmatimes
June 21, 2018
US regulators have again expanded the list of approved uses of MSD’s immunotherapy Keytruda, issuing a green light for the treatment of primary mediastinal large B-cell lymphoma (PMBCL).
Merck impresses NICE with Keytruda data—and discounts—cueing up a CDF switch fiercepharma
June 11, 2018
England's cost watchdogs have recommended moving Merck's Keytruda off the Cancer Drugs Fund and making it available for routine use. (Merck)
AbbVie's Humira, Merck's Keytruda and more: The top 10 drugs of 2024 fiercepharma
June 08, 2018
Even as many things change in the drug industry, at least one fact should stay the same in the coming years, according to analysts at EvaluatePharma.
Keytruda offers significant hope in subset of prostate cancer pharmafile
June 07, 2018
Up until present, no studies had shown that immunotherapies could offer potential treatment for men with prostate cancer; however, at ASCO, a team from The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust were able to use MSD’s Keyt
Merck's Keytruda, Roche's Tecentriq may lag chemo in some cancer patients, FDA says fiercepharma
May 23, 2018
Merck and Roche’s immunotherapies are each approved solo for certain previously untreated bladder cancer patients. But for other frontline patients, the drugs may be hurting their survival chances.
Incyte wipes out late-phase epacadostat program after pivotal failure of Keytruda combination fiercebiotech
May 02, 2018
Incyte has taken an ax to its suite of late-phase epacadostat trials after digesting the implications of last month’s pivotal study blowup.
‘Keytruda is King’ in lung cancer, putting BMS and next-gen in the shade pharmaphorum
April 18, 2018
Merck & Co is pressing home its precious advantage in first line non-small cell lung cancer, with new data from a Keytruda + chemo combination suggesting patients’ lives could be significantly extended.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 16 17 Next page